LeonaBio

LeonaBio Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of LeonaBio (LONA) as of Oct 21, 2026 is 1.91. In the previous year, Net Debt to Free Cash Flow Ratio was 0.51 — a change of 271.67% (higher).

Net Debt/FCF

1.91

YoY

271.67%

Last updated:

Net Debt to Free Cash Flow Ratio of LeonaBio is 2025 1.91 . Net Debt to Free Cash Flow Ratio of LeonaBio was 2024 0.51 . It decreases by 271.67% higher compared to the previous year.

The LeonaBio Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.91 USD
Jan 1, 2019
0.14 USD
Jan 1, 2020
6.95 USD
Jan 1, 2021
5.64 USD
Jan 1, 2022
2.70 USD
Jan 1, 2023
1.44 USD
Jan 1, 2024
0.51 USD
Jan 1, 2025
1.91 USD
The LeonaBio Net Debt/FCF history
YEARNet Debt/FCFYoY
1.91+271.67%
0.51-64.31%
1.44-46.47%
2.70-52.18%
5.64-18.87%
6.95+5,029.52%
0.14-85.17%
0.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Net Debt to Free Cash Flow Ratio of LeonaBio is 1.91 in 2025.

Net Debt to Free Cash Flow Ratio of LeonaBio changed from 0.51 to 1.91, representing a 271.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LeonaBio

All Key Metrics — LeonaBio